[Form 4] Applied Therapeutics, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Applied Therapeutics director Teena Lerner reported the conversion and cancellation of her equity holdings in connection with a completed merger. Under a Merger Agreement with Cycle Group Holdings Limited and AT2B, INC., a tender offer was followed by a merger effective as of January 28, 2026.
At the effective time, each common share was cancelled and converted into the right to receive $0.088 in cash per share plus one non‑tradeable contingent value right. All RSUs vested and were converted into the same merger consideration. Out‑of‑the‑money stock options, including several grants listed in the filing, were fully vested then cancelled for no consideration, leaving Lerner with no remaining common stock or options.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Lerner Teena
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 20,460 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 10,230 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 16,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 16,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 200,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 23,941 | $0.00 | -- |
| Disposition | Common Stock | 22,500 | $0.00 | -- |
| U | Common Stock | 82,922 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 82,922 shares (Direct)
Footnotes (1)
- Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration"). Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration. Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.
